Latest market price
10.67
-0.02-0.19%
CLPTQT22ClearPoint Neuro, Inc.·NASDAQ
10.67-0.19%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-1.21Insider Own5.14%Shs Outstand32.05MPerf Week16.74%
Market Cap342.02MForward P/E—EPS next Y-1.10Insider Trans-6.58%Shs Float27.62MPerf Month-6.81%
Enterprise Value370.02MPEG—EPS next Q—Short Float16.76%Perf Quarter-30.62%
Income-36.00MP/S7.60EPS this Y—Short Ratio7.01Perf Half Y-6.16%
Sales45.00MP/B12.67EPS next Y—ROA-32.05%Short Interest4.63MPerf YTD-22.00%
Book/sh0.84P/C7.44EPS next 5Y—ROE-170.24%52W High24.98 -57.29%Perf Year-55.74%
Cash/sh1.44P/FCF—EPS past 3/5Y—ROIC-31.12%52W Low8.27 29.02%Perf 3Y88.85%
Dividend Est.—EV/EBITDA—Sales past 3/5Y20.78% 23.27%Gross Margin61.39%Volatility8.72% 5.96%Perf 5Y-39.34%
Dividend TTM—EV/Sales8.22EPS Y/Y TTM—Oper. Margin-70.56%ATR (14)0.74Perf 10Y113.40%
Dividend Ex-Date—Quick Ratio5.77Sales Y/Y TTM32.35%Profit Margin-79.43%RSI (14)48.92Recom2.00
Dividend Gr. 3/5Y—Current Ratio6.76EPS Q/Q-14.29%SMA207.22%Beta1.33Target Price21.50
Payout0.00%Debt/Eq2.74Sales Q/Q33.33%SMA50-14.68%Rel Volume1.34Prev Close10.69
Employees172LT Debt/Eq2.74EarningsMar 16SMA200-17.68%Avg Volume683.24KPrice10.67
IPO DateMay 22, 2012Option/ShortYes / YesEPS/Sales Surpr.23.81% -1.83%Net Debt/EBITDA—Volume915,405Change-0.19%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedStifel Nicolaus$22 → $18
Aug-04-26ReiteratedLake StreetBuy$30 → $25
Aug-04-26ReiteratedStifel Nicolaus$25 → $22
Jun-09-26ReiteratedStifel Nicolaus$9.00 → $16
Jan-21-25ReiteratedLake StreetBuy$30
Aug-27-24ReiteratedLoop Capital Markets$15
Mar-13-24ReiteratedStifel Nicolaus$9.00
Latest News· Times ET
Oct-28-26
Oct-27-26
Oct-26-26
Oct-20-26
Oct-14-26
Oct-13-26
Oct-07-26
Oct-06-26
Oct-01-26
Sep-29-26
Sep-14-26
Sep-04-26
Company

ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue45373124—————
Cost of Goods Sold Incl. D&A18141210—————
Gross Profit28231914—————
Selling, General and Administrative Excl. Other44332624—————
Research and Development17141212—————
Other Operating Expense-2010—————
Operating Income-31-24-20-22—————
Interest Expense4200—————
Unusual Expense
—————————
Non-Operating Income (Expense)0110—————
Net Income Before Taxes-36-25-19-22—————
Income Taxes
0000—————
Consolidated Net Income-36-26-19-22—————
Net Income From Continuing Operations-36-26-19-22—————
Net Income-36-26-19-22—————
EPS (Recurring)-1.21-0.90-0.70-0.90—————
EPS (Basic, Before Extraordinaries)-1.21-0.90-0.70-0.90—————
EPS (Diluted)-1.21-0.90-0.70-0.90—————
EBITDA-27-21-17-21—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio7.3510.3513.407.07—————
Gross Margin62.2262.1661.2958.33—————
Operating Margin-68.89-64.86-64.52-91.67—————
Net Margin-80.00-70.27-61.29-91.67—————
Shares Outstanding31282725—————
Market Capitalization331383415170—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$32.74$25.94$19.13$12.32$5.52● Close Price0.00M0.39M0.78M1.17M1.55MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BURNETT JOSEPHCEO and PresidentSep 02 '26Option Exercise3.4712,51743,434130,720Sep 03
BURNETT JOSEPHCEO and PresidentJun 29 '26Option Exercise2.5020,00050,000136,842Jul 01
BURNETT JOSEPHCEO and PresidentJun 29 '26Sale19.3820,000387,600116,842Jul 01
BURNETT JOSEPHCEO and PresidentJun 17 '26Sale17.7961,8431,100,463116,842Jun 22
BURNETT JOSEPHCEO and PresidentJun 17 '26Option Exercise2.5060,000150,000176,842Jun 22
Richards Timothy T.DirectorJun 04 '26Option Exercise10.005005,00087,698Jun 08
Richards Timothy T.DirectorJun 01 '26Sale12.175,41565,90187,198Jun 02
Klein Matthew B.DirectorMay 21 '26Sale11.5916,000185,44046,935May 26
FALLON LYNNETTE CDirectorMay 20 '26Sale11.145,09156,71448,227May 21
FLETCHER R JOHNDirectorMay 19 '26Option Exercise0.0012,4170130,349May 21
Klein Matthew B.DirectorMay 19 '26Option Exercise0.0012,417062,935May 21
FALLON LYNNETTE CDirectorMay 19 '26Option Exercise0.0012,417053,318May 21
Richards Timothy T.DirectorMay 19 '26Option Exercise0.0012,417092,613May 21
JOHNSON B KRISTINEDirectorMay 19 '26Option Exercise0.0012,417071,116May 21
Girin Pascal E RDirectorMay 19 '26Option Exercise0.0012,4170110,623May 21
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.